WOMEN of reproductive age in Nigeria are amongst 300,000 women in low-resource settings who stand to benefit from the findings of an eight-year trial on the effectiveness of a novel human papillomavirus (HPV) scanning kit.
Led by Dr. Rengaswamy Sankaranarayanan of the International Agency for Research on Cancer (IARC), the randomized, controlled trial compared the efficacy of three methods of cervical cancer screening - VIA, Pap testing (cytology) and HPV testing with a hybrid capture 2 DNA testing technology (called the digene HPV Test).
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article
